Chronic Urticaria Or Hives – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Chronic Urticaria Or Hives – Pipeline Review, H1 2017’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives

The report reviews pipeline therapeutics for Chronic Urticaria Or Hives by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Urticaria Or Hives therapeutics and enlists all their major and minor projects

The report assesses Chronic Urticaria Or Hives therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biofrontera AG

ELORAC Inc

Faes Farma SA

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

J Uriach Y Compania SA

Mycenax Biotech Inc

Novartis AG

Panacea Biotec Ltd

Synermore Biologics Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Urticaria Or Hives - Overview

Chronic Urticaria Or Hives - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Urticaria Or Hives - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development

Biofrontera AG

ELORAC Inc

Faes Farma SA

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

J Uriach Y Compania SA

Mycenax Biotech Inc

Novartis AG

Panacea Biotec Ltd

Synermore Biologics Co Ltd

Chronic Urticaria Or Hives - Drug Profiles

BF-Derm-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetirizine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cidoxepin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-0853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2646264 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ligelizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rupatadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Urticaria Or Hives - Dormant Projects

Chronic Urticaria Or Hives - Discontinued Products

Chronic Urticaria Or Hives - Product Development Milestones

Featured News & Press Releases

Jan 25, 2017: Pediapharm Announces the Commercial Launch of Rupall (Rupatadine) in Canada

Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada

Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan

Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan

Jul 22, 2016: Uriach receives Health Canada approval for rupatadine

Jul 21, 2016: Pediapharm Receives Health Canada Approval for Rupatadine

Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN

Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan

May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration

Jul 09, 2012: Uriach Extends Collaboration With Hyphens On Rupafin Oral Solution

Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico

Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil

Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain

Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries

Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chronic Urticaria Or Hives – Pipeline by Biofrontera AG, H1 2017

Chronic Urticaria Or Hives – Pipeline by ELORAC Inc, H1 2017

Chronic Urticaria Or Hives – Pipeline by Faes Farma SA, H1 2017

Chronic Urticaria Or Hives – Pipeline by Genentech Inc, H1 2017

Chronic Urticaria Or Hives – Pipeline by GlaxoSmithKline Plc, H1 2017

Chronic Urticaria Or Hives – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Chronic Urticaria Or Hives – Pipeline by J Uriach Y Compania SA, H1 2017

Chronic Urticaria Or Hives – Pipeline by Mycenax Biotech Inc, H1 2017

Chronic Urticaria Or Hives – Pipeline by Novartis AG, H1 2017

Chronic Urticaria Or Hives – Pipeline by Panacea Biotec Ltd, H1 2017

Chronic Urticaria Or Hives – Pipeline by Synermore Biologics Co Ltd, H1 2017

Chronic Urticaria Or Hives – Dormant Projects, H1 2017

Chronic Urticaria Or Hives – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Chronic Urticaria Or Hives, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports